PMID- 27256098
OWN - NLM
STAT- MEDLINE
DCOM- 20170301
LR  - 20181113
IS  - 1559-0097 (Electronic)
IS  - 1046-3976 (Linking)
VI  - 27
IP  - 3
DP  - 2016 Sep
TI  - Expression of Somatostatin Receptor Type 2A and PTEN in Neuroendocrine Neoplasms 
      Is Associated with Tumor Grade but Not with Site of Origin.
PG  - 179-87
LID - 10.1007/s12022-016-9436-5 [doi]
AB  - Neuroendocrine neoplasms (NENs) are derived from endocrine cells in various 
      organs and share common morphological features. This study aimed to clarify 
      whether NENs of different organs are comparable at the molecular pathologic 
      level. We retrospectively collected 99 cases of NENs from 
      gastro-entero-pancreatic, lung, and other organs and reclassified these according 
      to identical criteria. Grade, site, and molecular expression profile including NE 
      markers, Ki-67, p53, somatostatin receptor type 2A (SSTR2A), and phosphatase and 
      tensin homolog (PTEN) were compared. PTEN immunoreactivity was also compared with 
      genomic copy number by fluorescence in situ hybridization (FISH) and droplet 
      digital polymerase chain reaction (ddPCR). No significant differences were 
      observed in the immunoreactivities of NE markers, p53, SSTR2A, or PTEN expression 
      in NENs between the different organ sites. PTEN and p53 functional inactivation 
      along with the loss of membranous SSTR2A expression appeared to be commonly 
      involved in high-grade NEN. FISH results were significantly correlated with the 
      level of PTEN immunoreactivity and with the findings of ddPCR analyses. The 
      demonstration that these tumors are comparable at the molecular level will likely 
      contribute to the broadening of therapeutic options such as the use of 
      somatostatin analogues and mTOR inhibitors against NENs regardless of the 
      affected organ, whereas molecular characterization of tumor grade will be useful 
      for determining treatment strategy.
FAU - Wada, Hideo
AU  - Wada H
AD  - Division of Surgical Oncology, Nagasaki University Graduate School of Biomedical 
      Sciences, 1-7-1 Sakamoto, Nagasaki, 852 8501, Japan.
AD  - Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, 
      Nagasaki University Graduate School of Biomedical Sciences, 1-12-4 Sakamoto, 
      Nagasaki, 852 8523, Japan.
FAU - Matsuda, Katsuya
AU  - Matsuda K
AD  - Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, 
      Nagasaki University Graduate School of Biomedical Sciences, 1-12-4 Sakamoto, 
      Nagasaki, 852 8523, Japan.
FAU - Akazawa, Yuko
AU  - Akazawa Y
AD  - Department of Gastroenterology and Hepatology, Nagasaki University Hospital, 
      1-7-1 Sakamoto, Nagasaki, 852 8501, Japan.
FAU - Yamaguchi, Yuka
AU  - Yamaguchi Y
AD  - Medical Student Research Programme, Nagasaki University School of Medicine, 
      1-12-4 Sakamoto, Nagasaki, 852 8523, Japan.
FAU - Miura, Shiro
AU  - Miura S
AD  - Tissue and Histopathology Section, Atomic Bomb Disease Institute, Nagasaki 
      University, 1-12-4 Sakamoto, Nagasaki, 852 8523, Japan.
FAU - Ueki, Nozomi
AU  - Ueki N
AD  - Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, 
      Nagasaki University Graduate School of Biomedical Sciences, 1-12-4 Sakamoto, 
      Nagasaki, 852 8523, Japan.
FAU - Kinoshita, Akira
AU  - Kinoshita A
AD  - Department of Human Genetics, Atomic Bomb Disease Institute, Nagasaki University 
      Graduate School of Biomedical Sciences, 1-12-4 Sakamoto, Nagasaki, 852 8523, 
      Japan.
FAU - Yoshiura, Koh-Ichiro
AU  - Yoshiura K
AD  - Department of Human Genetics, Atomic Bomb Disease Institute, Nagasaki University 
      Graduate School of Biomedical Sciences, 1-12-4 Sakamoto, Nagasaki, 852 8523, 
      Japan.
FAU - Kondo, Hisayoshi
AU  - Kondo H
AD  - Biostatic section, Atomic Bomb Disease Institute, Nagasaki University Graduate 
      School of Biomedical Sciences, 1-12-4 Sakamoto, Nagasaki, 852 8523, Japan.
FAU - Ito, Masahiro
AU  - Ito M
AD  - Department of Pathology, National Hospital Organization Nagasaki Medical Center, 
      2-1001-1 Kubara, Nagasaki, 856 8562, Japan.
FAU - Nagayasu, Takeshi
AU  - Nagayasu T
AD  - Division of Surgical Oncology, Nagasaki University Graduate School of Biomedical 
      Sciences, 1-7-1 Sakamoto, Nagasaki, 852 8501, Japan.
FAU - Nakashima, Masahiro
AU  - Nakashima M
AD  - Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, 
      Nagasaki University Graduate School of Biomedical Sciences, 1-12-4 Sakamoto, 
      Nagasaki, 852 8523, Japan. moemoe@nagasaki-u.ac.jp.
AD  - Tissue and Histopathology Section, Atomic Bomb Disease Institute, Nagasaki 
      University, 1-12-4 Sakamoto, Nagasaki, 852 8523, Japan. moemoe@nagasaki-u.ac.jp.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Endocr Pathol
JT  - Endocrine pathology
JID - 9009288
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Somatostatin)
RN  - 0 (SSTR2 protein, human)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
RN  - EC 3.1.3.67 (PTEN protein, human)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/analysis
MH  - Female
MH  - Gene Dosage
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neuroendocrine Tumors/*genetics/*pathology
MH  - PTEN Phosphohydrolase/*genetics
MH  - Polymerase Chain Reaction
MH  - Proportional Hazards Models
MH  - Receptors, Somatostatin/*biosynthesis
MH  - Retrospective Studies
MH  - Young Adult
OTO - NOTNLM
OT  - FISH
OT  - Neuroendocrine neoplasm
OT  - PTEN
OT  - SSTR2A
OT  - ddPCR
OT  - p53
EDAT- 2016/06/04 06:00
MHDA- 2017/03/03 06:00
CRDT- 2016/06/04 06:00
PHST- 2016/06/04 06:00 [entrez]
PHST- 2016/06/04 06:00 [pubmed]
PHST- 2017/03/03 06:00 [medline]
AID - 10.1007/s12022-016-9436-5 [pii]
AID - 10.1007/s12022-016-9436-5 [doi]
PST - ppublish
SO  - Endocr Pathol. 2016 Sep;27(3):179-87. doi: 10.1007/s12022-016-9436-5.